A scoping review on quality assessment tools used in systematic reviews and meta-analysis of real-world studies

por Gebrye, Tadesse, Fatoye, Francis, Mbada, Chidozie, Hakimi, Zalmai
Publicado 2023

Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison

por Hakimi, Zalmai, Santagostino, Elena, Postma, Maarten J., Nazir, Jameel
Publicado 2020

Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated wi...

por Nazir, Jameel, Heemstra, Lars, van Engen, Anke, Hakimi, Zalmai, Ivanescu, Cristina
Publicado 2015

Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder

por Desroziers, Katia, Aballéa, Samuel, Maman, Khaled, Nazir, Jameel, Odeyemi, Isaac, Hakimi, Zalmai
Publicado 2013

Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review

por Yeowell, Gillian, Smith, Philip, Nazir, Jameel, Hakimi, Zalmai, Siddiqui, Emad, Fatoye, Francis
Publicado 2018

Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials

por Astermark, Jan, Wojciechowski, Piotr, Aballéa, Samuel, Hakimi, Zalmai, Nazir, Jameel, Klamroth, Robert
Publicado 2021

Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France

por Wojciechowski, Piotr, Wdowiak, Marlena, Hakimi, Zalmai, Wilson, Koo, Fishman, Jesse, Nazir, Jameel, Toumi, Mondher
Publicado 2023

Elicitation of Health-related Quality-of-life Concepts Associated with Overactive Bladder: A Qualitative Study

por Hawken, Natalia, Hakimi, Zalmai, Aballéa, Samuel, Nazir, Jameel, O. Odeyemi, Isaac A., Toumi, Mondher
Publicado 2016

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK

por Hakimi, Zalmai, Kelleher, Con, Aballéa, Samuel, Maman, Khaled, Nazir, Jameel, Mankowski, Colette, Odeyemi, Isaac
Publicado 2018

Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophylaxis: post hoc analysis from the A-LONG study

por Pasi, John, Hermans, Cédric, Hakimi, Zalmai, Nazir, Jameel, Aballéa, Samuel, Ezzalfani, Monia, Fatoye, Francis
Publicado 2022

Efficacy of rFIXFc versus N9-GP Prophylaxis in Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PARADIGM 2 Trials

por Mancuso, Maria Elisa, Eriksson, Daniel, Falk, Aletta, Hakimi, Zalmai, Wojciechowski, Piotr, Wdowiak, Marlena, Klamroth, Robert
Publicado 2023

A retrospective study of treatment persistence and adherence to α-blocker plus antimuscarinic combination therapies, in men with LUTS/BPH in the Netherlands

por Drake, Marcus J., Bowditch, Sally, Arbe, Emilio, Hakimi, Zalmai, Guelfucci, Florent, Amri, Ikbel, Nazir, Jameel
Publicado 2017

Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK

por Nazir, Jameel, Berling, Malin, McCrea, Charles, Fatoye, Francis, Bowditch, Sally, Hakimi, Zalmai, Wagg, Adrian
Publicado 2017

S300: ASSESSMENT OF JOINT HEALTH IN PATIENTS RECEIVING PROPHYLAXIS FOR HAEMOPHILIA A IN FIVE EUROPEAN COUNTRIES: A CROSS-SECTIONAL SURVEY

por De la Corte‐rodriguez, Hortensia, Bystrická, Linda, Ball, Nathan, Olsen, Stevie, Golden, Keisha, Hakimi, Zalmai, Kragh, Nana
Publicado 2023

Content validity and test-retest reliability of patient perception of intensity of urgency scale (PPIUS) for overactive bladder

por Notte, Sherilyn M, Marshall, Thomas S, Lee, Misun, Hakimi, Zalmai, Odeyemi, Isaac, Chen, Wen-Hung, Revicki, Dennis A
Publicado 2012

A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain

por Nazir, Jameel, Hakimi, Zalmai, Guelfucci, Florent, Khemiri, Amine, Fatoye, Francis, Blázquez, Ana María Mora, González, Marta Hernández
Publicado 2018

Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK

por Kragh, Nana, Tytula, Anna, Pochopien, Michał, Aballéa, Samuel, Toumi, Mondher, Hakimi, Zalmai, Nazir, Jameel, Bystrická, Linda, Fatoye, Francis
Publicado 2022

Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom

por Aballéa, Samuel, Maman, Khaled, Thokagevistk, Katia, Nazir, Jameel, Odeyemi, Isaac A. O., Hakimi, Zalmai, Garnham, Andy, Toumi, Mondher
Publicado 2014

Health-related quality of life, direct medical and societal costs among children with moderate or severe haemophilia in Europe: multivariable models of the CHESS-PAEDs study

por Rodriguez-Santana, Idaira, DasMahapatra, Pronabesh, Burke, Tom, Hakimi, Zalmai, Bartelt-Hofer, José, Nazir, Jameel, O’Hara, Jamie
Publicado 2022

Differential humanistic and economic burden of mild, moderate and severe haemophilia in european adults: a regression analysis of the CHESS II study

por Rodriguez-Santana, Idaira, DasMahapatra, Pronabesh, Burke, Tom, Hakimi, Zalmai, Bartelt-Hofer, José, Nazir, Jameel, O’Hara, Jamie
Publicado 2022